All In Biotech

Drug Trial Radar · NCT02899364

Sodium Thiosulfate to Preserve Cardiac Function in STEMI

Groningen Intervention Study for the Preservation of Cardiac Function With Sodium Thiosulfate After ST-segment Elevation Myocardial Infarction

Last checked: Nov 19, 2026Latest source record: Sep 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

380

Planned (sponsor's estimate)

Start

Jul 20, 2018

Primary completion

Jun 25, 2021

Study completion Mar 2023

Sponsor

Lead sponsor
University Medical Center GroningenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 14, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Rationale: Timely and effective reperfusion by primary percutaneous coronary intervention (PPCI) is currently the most effective treatment of ST-segment elevation myocardial infarction (STEMI). However, permanent myocardial injury related to the ischemia and subsequent reperfusion is observed in the vast majority (88%) of patients and harbours a risk of heart failure development. Administration of hydrogen sulfide (H2S) has been shown to protect the heart from "ischemia reperfusion injury" in various experimental models. Data in humans suggests that the H2S-releasing agent sodium thiosulfate (STS) can be administered safely. Objective: to evaluate the efficacy and safety of STS compared to placebo treatment on myocardial infarct size in patients presenting with STEMI and treated with PCI Study design: a multicenter, double blind, randomized controlled clinical trial. A total of 380 patients, aged 18 years and above, undergoing primary PCI for a first STEMI and deemed amenable, by the investigator, to be treated with STS 12.5g intravenously (i.v.) or matched placebo immediately after arrival at the catheterization laboratory (cath-lab) and a repeated dose administered 6 hours after the first dose, on top of standard treatment. Primary endpoint is infarct size as measured with cardiac magnetic resonance imaging (CMR-imaging) 4 months after randomization.

Conditions

  • Myocardial Infarction
  • Heart Failure

Interventions

  • Sodium thiosulfateDrug

    see description under experimental arm

  • Sodium chloride 0.9%Drug

    see description under placebo comparator arm

  • primary percutaneous coronary interventionProcedure

    Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.

  • cardiac magnetic resonance imagingOther

    CMR-imaging will be used for assessment of infarct size, left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Myocardial infarct size as measured with late gadolinium enhancement cardiac magnetic resonance imaging.Time frame: 4 months after randomization

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University Medical Centre Groningen

    Groningen, Netherlands

  • University Medical Center Utrecht

    Utrecht, Netherlands

  • Treant Scheper Hospital

    Emmen, Drenthe, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.